Emily Karanges

"There are ways … drug companies will get into DTC decisions": How Australian drug and therapeutics committees address pharmaceutical industry influence.

Lisa Parker, Alexandra Bennett, Barbara Mintzes, Quinn Grundy, Alice Fabbri, Emily A Karanges, Lisa Bero

Journal article  |  2020  |  British Journal of Clinical Pharmacology

AIMS: One tool for protecting quality use of medicines in hospitals is a drug and therapeutics committee (DTC) that oversees medic..

Pharmaceutical industry payments to leaders of professional medical associations in Australia: Focus on cardiovascular disease and diabetes.

Emily A Karanges, Natasha Ting, Lisa Parker, Alice Fabbri, Lisa Bero

Journal article  |  2020  |  AfP

BACKGROUND AND OBJECTIVES: Pharmaceutical industry interactions with professional medical associations have come under scrutiny, y..

Policies affecting the supply and access of opioid analgesics: a scoping review protocol.

Kellia Chiu, Sally McDonald, Tess Legg, Emily A Karanges, Lisa Bero

Journal article  |  2019  |  The JBI Database of Systematic Reviews and Implementation Reports

OBJECTIVE: This scoping review aims to describe and map the range of evaluated policies that affect the supply and access of opioi..

Pharmaceutical industry funding of events for healthcare professionals on non-vitamin K oral anticoagulants in Australia: an observational study.

Behrad Behdarvand, Emily A Karanges, Lisa Bero

Journal article  |  2019  |  BMJ Open

OBJECTIVES: To describe the nature, frequency and content of non-vitamin K oral anticoagulant (NOAC)-related events for healthcare..

Understanding the Nature and Extent of Pharmaceutical Industry Payments to Nonphysician Clinicians.

Emily A Karanges, Quinn Grundy, Lisa Bero

Journal article  |  2019  |  JAMA Internal Medicine

Trends in self-poisoning and psychotropic drug use in people aged 5-19 years: a population-based retrospective cohort study in Australia

Rose Cairns, Emily A Karanges, Anselm Wong, Jared A Brown, Jeff Robinson, Sallie-Anne Pearson, Andrew H Dawson, Nicholas A Buckley

Journal article  |  2019  |  BMJ Open

Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study.

Lisa Parker, Emily A Karanges, Lisa Bero

Journal article  |  2019  |  BMJ Open

OBJECTIVES: To describe and quantify disclosed payments from the pharmaceutical industry to the healthcare sector, and to examine ..

Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population-based study

Andrea L Schaffer, Emily A Karanges, Nicholas A Buckley, Andrew Wilson, Louisa Degenhardt, Briony Larance, Sallie-Anne Pearson

Conference Proceedings  |  2019  |  Pharmacoepidemiology and Drug Safety

PURPOSE: Despite increasing use of oxycodone/naloxone controlled-release (CR) in Australia, little is known about how it has affec..

Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey.

Emily A Karanges, Anastasia Suraev, Natalie Elias, Ramesh Manocha, Iain S McGregor

Journal article  |  2018  |  BMJ Open

OBJECTIVES: To examine the knowledge and attitudes of Australian general practitioners (GP) towards medicinal cannabis, including ..

Prescription Opioid Access Patterns and Factors Associated with Increasing Number of Prescribers, Pharmacies, and Dispensings: An Observational Study Using Pharmaceutical Claims

Bianca Blanch, Louisa Degenhardt, Nicholas A Buckley, Natasa Gisev, Timothy Dobbins, Emily A Karanges, Briony Larance, Sarah Larney, Sallie-Anne Pearson

Journal article  |  2018  |  Pain Medicine